Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…

This study tests an experimental drug called KL590586 in people with advanced solid tumors that have a specific change in the RET gene. The goal is to see if the drug is safe and can shrink tumors. About 414 adults who have not responded to standard treatments will take the capsu…

This study tests a new drug called SKB264 against standard chemotherapy in people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to targeted therapy (EGFR-TKI). About 376 participants will be randomly assigned to…

This study tests a new drug called SKB264 in people with advanced triple-negative breast cancer that has not responded to at least two prior treatments. About 254 participants will receive either SKB264 or another standard treatment chosen by their doctor. The goal is to see if S…

This phase 3 trial tests whether adding the experimental drug KL-A167 to standard chemotherapy (cisplatin and gemcitabine) helps people with recurrent or metastatic nasopharyngeal carcinoma live longer without their cancer growing. About 295 adults aged 18–75 are participating. T…

This phase 3 trial compares a new drug called A166 to the standard drug T-DM1 in about 365 people with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. Participants must have already been treated with trastuzumab and a taxane…

This study tests a new drug (SKB264) alone or with another drug (KL-A167) in people with advanced HER2-negative breast cancer that hasn't been treated yet. The goal is to see if the combination is safe and shrinks tumors. About 175 adults with triple-negative or HR+/HER2- breast …

This early-stage study tests a new drug called A166 in 120 adults with advanced HER2-positive solid tumors that have spread or cannot be removed by surgery. The main goal is to check safety and find the right dose, while also seeing if the drug shrinks tumors. Participants must h…

This study tests a new drug called SKB264 in people with advanced solid tumors (like lung or nasopharyngeal cancer) that have not responded to other treatments. The goal is to see if the drug can shrink tumors and how safe it is. Participants receive the drug until it stops worki…

This study tests a new drug called SKB264 in 20 women with ovarian cancer that has come back. The goal is to see if the drug shrinks tumors and how the body processes it. Participants receive the drug and are monitored for safety and effectiveness.

This study tests whether adding the experimental drug SKB264 to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). About 406 participants who have not had …